FindTrial
Sign In

AT-101

DRUG10 trials

Sponsors

Ascenta Therapeutics, National Cancer Institute (NCI), University of Michigan Rogel Cancer Center

Conditions

Adenocarcinoma of the ProstateChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaFollicular LymphomaHormone Refractory Prostate CancerLaryngeal CancerLocally Advanced Esophageal or GE Junction CancerMantle Cell Lymphoma

Phase 1

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
CompletedNCT00286806
Ascenta TherapeuticsHormone Refractory Prostate Cancer
Start: 2005-12-31End: 2007-06-30Target: 27Updated: 2010-08-24
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
CompletedNCT00286793
Ascenta TherapeuticsProstate Cancer
Start: 2006-02-28End: 2009-11-30Updated: 2011-06-29
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
CompletedNCT00397293
Ascenta TherapeuticsSmall Cell Lung Cancer
Start: 2006-11-30End: 2008-12-31Updated: 2010-08-24
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
TerminatedNCT00561197
Ascenta TherapeuticsLocally Advanced Esophageal or GE Junction Cancer
Start: 2007-08-31End: 2010-09-30Updated: 2013-01-04

Phase 2

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
CompletedNCT00275431
Ascenta TherapeuticsChronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Follicular Lymphoma +2
Start: 2005-11-30End: 2008-12-31Updated: 2011-06-29
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
CompletedNCT00286780
Ascenta TherapeuticsChronic Lymphocytic Leukemia
Start: 2006-01-31End: 2007-11-30Updated: 2010-08-13
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
CompletedNCT00440388
Ascenta TherapeuticsFollicular Lymphoma
Start: 2006-10-31End: 2008-11-30Updated: 2010-08-27
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
CompletedNCT00666666
National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Start: 2009-07-31End: 2012-06-30Updated: 2014-12-18
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
TerminatedNCT01285635
University of Michigan Rogel Cancer CenterSquamous Cell Carcinoma of the Head and Neck (SCCHN)
Start: 2010-06-30End: 2015-09-30Updated: 2016-03-31
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
CompletedNCT01633541
University of Michigan Rogel Cancer CenterLaryngeal Cancer
Start: 2012-03-31End: 2021-11-06Updated: 2023-07-20

Related Papers

A randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
Journal of Clinical Oncology2019-05-203 citations